beam therapeutics inc american biotechnology company conducting research field gene therapies genome editing company headquartered cambridge massachusetts development therapies company relies crispr prime editing whereby single nucleotides dna sequence modified without cutting dna theoretically reducing likelihood offtarget effects compared previous crisprbased founded company traces origins broad institute massachusetts institute technology harvard university cofounders include david r liu feng prior ipo company raised nearly billion venture capital investors february ipo company raised january pfizer beam therapeutics announced collaboration develop therapies rare diseases using httpsenwikipediaorgwikibeamtherapeutics